Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Capital Expenditures (2016 - 2025)

CorMedix's Capital Expenditures history spans 13 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 16865.22% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $2.3 million, up 1848.28%, while the annual FY2025 figure was $2.3 million, 1848.28% up from the prior year.
  • Capital Expenditures for Q4 2025 was $1.7 million at CorMedix, up from $505774.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.7 million in Q4 2025 and bottomed at $4324.0 in Q1 2022.
  • The 5-year median for Capital Expenditures is $23945.0 (2025), against an average of $237379.7.
  • The largest annual shift saw Capital Expenditures tumbled 90.18% in 2022 before it soared 16865.22% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $628761.0 in 2021, then plummeted by 79.52% to $128755.0 in 2022, then crashed by 88.53% to $14766.0 in 2023, then crashed by 31.34% to $10139.0 in 2024, then skyrocketed by 16865.22% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Capital Expenditures are $1.7 million (Q4 2025), $505774.0 (Q3 2025), and $23945.0 (Q2 2025).